AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
38.95
-0.34 (-0.87%)
At close: 4:03PM EDT

38.99 +0.04 (0.10%)
After hours: 4:26PM EDT

Stock chart is not supported by your current browser
Previous Close39.29
Open39.11
Bid38.30 x 4000
Ask39.40 x 4000
Day's Range38.71 - 39.20
52 Week Range31.99 - 40.16
Volume5,896,267
Avg. Volume4,039,620
Market Cap96.868B
Beta (3Y Monthly)0.53
PE Ratio (TTM)36.92
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.40 (3.74%)
Ex-Dividend Date2018-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • 2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
    Motley Foolyesterday

    2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report

    Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.

  • Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
    Yahoo Finance2 days ago

    Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional

    The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.

  • AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
    Zacks2 days ago

    AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

    AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

  • Reuters3 days ago

    May says Irish backstop can't derail deadlocked Brexit talks

    Prime Minister Theresa May urged the EU on Monday not to allow a stand-off over a 'backstop' for Ireland to derail Brexit talks, saying she believed a deal was still achievable as a top EU official said chances of a no-deal divorce had increased. Addressing a rowdy session of parliament before she headed to Brussels for a summit on Wednesday, May remained upbeat but repeated she would not agree to anything that could split the United Kingdom.

  • Reuters3 days ago

    AstraZeneca will keep UK investment freeze if no Brexit clarity

    AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

  • AstraZeneca will keep UK investment freeze if no Brexit clarity
    Reuters3 days ago

    AstraZeneca will keep UK investment freeze if no Brexit clarity

    AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.

  • Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
    Reuters3 days ago

    Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

    Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.

  • 3 Large-Cap Pharma Stocks Performing Better Than Industry
    Zacks6 days ago

    3 Large-Cap Pharma Stocks Performing Better Than Industry

    We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

  • J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
    Zacks6 days ago

    J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion

    Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.

  • Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
    Zacks7 days ago

    Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

    Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.

  • 3 Dividend Stocks That Pay You Better Than Pepsi Does
    Motley Fool7 days ago

    3 Dividend Stocks That Pay You Better Than Pepsi Does

    Before you add Pepsi to your income portfolio, you might want to consider these three high-dividend-paying stocks.

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist7 days ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • A Closer Look at Novartis’s Innovative Medicines Segment
    Market Realist8 days ago

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

  • How Novartis’s Businesses Have Been Performing
    Market Realist9 days ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • Top Research Reports for JPMorgan, American Express & FedEx
    Zacks9 days ago

    Top Research Reports for JPMorgan, American Express & FedEx

    Top Research Reports for JPMorgan, American Express & FedEx

  • GW Pharmaceuticals: Q3 Performance, Q4 Estimates
    Market Realist13 days ago

    GW Pharmaceuticals: Q3 Performance, Q4 Estimates

    GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.

  • Novartis ADR’s Performance and Revenue Estimates for Q3 2018
    Market Realist14 days ago

    Novartis ADR’s Performance and Revenue Estimates for Q3 2018

    Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.

  • Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
    Market Realist15 days ago

    Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018

    The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.

  • 2 Stocks That Can Safely Double Your Money
    Motley Fool16 days ago

    2 Stocks That Can Safely Double Your Money

    AstraZeneca and Celgene Corporation are both outstanding buys for long-term-oriented investors. Here's why.

  • Roche Gets FDA Approval for New Formulation of Asthma Drug
    Zacks17 days ago

    Roche Gets FDA Approval for New Formulation of Asthma Drug

    Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.

  • How GlaxoSmithKline’s Segments Performed
    Market Realist17 days ago

    How GlaxoSmithKline’s Segments Performed

    GlaxoSmithKline (GSK) has three business segments: the Pharmaceuticals segment, the Vaccines segment, and the Consumer Healthcare segment. We’ll discuss how the company’s segments performed in this article.

  • AstraZeneca: Dividend Overview and Recent Developments
    Market Realist18 days ago

    AstraZeneca: Dividend Overview and Recent Developments

    On July 26, AstraZeneca announced a dividend of $0.45, which was paid on September 10. The dividend yield was 3.52%. AstraZeneca paid a dividend of $0.45 on September 10 to shareholders of record on August 10.

  • A Look at Eli Lilly’s Revenue Growth Rate
    Market Realist20 days ago

    A Look at Eli Lilly’s Revenue Growth Rate

    Eli Lilly and Company (LLY) reported revenue of ~$6.4 billion in the second quarter, surpassing Wall Street analysts’ estimates for revenue in the period.

  • Drug commercials you see on TV may be overhauled
    Yahoo Finance Video2 days ago

    Drug commercials you see on TV may be overhauled

    Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.